SORANIB

Soranib

Read more

Sorafenib is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys). Sorafenib is also used to treat hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery and a certain type of thyroid cancer that has spread to other parts of the body and cannot be treated with radioactive iodine. Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.This helps stop the spread of cancer cells.

Product Description

Sorafenib (co-created and co-advertised by Bayer and Onyx Pharmaceuticals as Nexavar),is a kinase inhibitor tranquilize endorsed for the treatment of essential kidney disease (progressed renal cell carcinoma), propelled essential liver growth (hepatocellular carcinoma) and radioactive iodine safe propelled thyroid carcinoma.

Component of activity

Sorafenib is a little inhibitor of a few tyrosine protein kinases, for example, VEGFR, PDGFR and Raf family kinases (more devotedly C-Raf than B-Raf)See BRAF Sorafenib for points of interest of medication structure communication with B-Raf.)

Sorafenib treatment initiates autophagy, which may smother tumor development. Be that as it may, autophagy can likewise cause sedate resistance.

Reviews

There are no reviews yet.

Be the first to review “Soranib”

Your email address will not be published. Required fields are marked *